In a systematic review and meta-analysis, researchers sought to compare outcomes associated with the use of lasmiditan, rimegepant, and ubrogepant vs triptans for the acute management of migraine headaches.
The HER-MES trial included 777 adults with episodic or chronic migraine (at least 4 migraine days/month) who were treatment-naïve, not suitable for, or had previously failed up to 3 prophylactic migraine treatments.
The analysis included 64 randomized clinical trials with a total of 46,442 patients.
A history of migraine prior to pregnancy is associated with anxiety and with mixed depression and anxiety in mid-pregnancy and late pregnancy, respectively.
In a double-blind, placebo-controlled, randomized study, researchers sought to determine the exact site of interaction between the occipital and trigeminal nerves and the mechanisms of this interaction.
The FDA has approved atogepant for the preventive treatment of episodic migraine in adults.
Race and income — both individually and combined — affect the incidence of migraine diagnosis on admission to the hospital.
A higher 24-hour urine sodium level is positively associated with worse migraine headache outcomes.
The use of triptans is contraindicated in patients with migraine and a history of ischemic stroke or coronary artery disease, although there’s no substantial evidence that they directly increase the risk for vascular events.
The use of 15 headache days/month as a threshold to distinguish episodic and chronic migraine does not capture the burden of illness.
